SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Opko Health Inc (OPK)

OPK RSS Feed
Add OPK Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/23/2017 10:42:41 AM - Followers: 165 - Board type: Free - Posts Today: 0

Opko Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD Wednesday July 11, 8:00 am ET -Trial Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Lucentis(R) Administered Every 4 Weeks- -Represents First-Ever Phase 3 Pivotal Trial of an RNAi Therapeutic- MIAMI, July 11 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced the initiation of the Phase 3 COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD.) The multi-national COBALT study is currently open and enrolling patients. The trial will include more than 330 wet AMD patients and will assess whether bevasiranib administered every 8 or 12 weeks is safe and has equivalent efficacy in preventing vision loss as Genentech's Lucentis® administered every four weeks. ADVERTISEMENT Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase 3 clinical trials. "This first-ever Phase 3 trial of an agent based on RNAi technology is an important milestone in this new field. We are proud of the ability demonstrated by our clinical group to have successfully moved this innovative compound through development rapidly and cost effectively," said Philip Frost, M.D., Chairman and CEO of Opko Health. "Currently patients with wet AMD undergo intravitreal injections every four weeks to achieve the vision- preserving benefits of Lucentis, so the potential ability of bevasiranib to achieve similar results while requiring less frequent injections would be an important benefit for these patients who often have limited mobility." "Bevasiranib's demonstrated safety profile, its ability to inhibit the growth of the retinal lesions associated with wet AMD and its potential for prolonged duration are a promising foundation for this pivotal trial," said Lawrence Singerman M.D., founder and Executive Secretary of the Macula Society, Clinical Professor of Ophthalmology at Case University and a Principal Investigator for the Phase 3 study. "Bevasiranib's potential to serve as a long-term maintenance therapy for wet AMD could provide important benefits to patients, and I look forward to helping to assess its utility in this groundbreaking study." "We are very pleased at the enthusiastic reception the COBALT trial has received from retinal centers around the globe," said Denis O'Shaughnessy, Ph.D., Senior Vice President of Clinical Development at Opko. "Retinal physicians are keenly aware of the burden that frequent drug injections places on elderly patients and their families, and they are eager to help test an innovative new approach that has the potential to significantly reduce that burden while preserving patients' vision." About Wet AMD Wet age-related macular degeneration is the leading cause of irreversible vision loss in the developed world and its incidence is growing rapidly. Advanced age is the main risk factor for wet AMD, and it is expected to become an increasingly common condition as the population grows older. An estimated 1.65 million Americans have wet AMD today and an estimated 11 million people worldwide will have AMD by 2013. Until recently, treatments for wet AMD were of limited efficacy. In the search for more effective treatments, researchers targeted VEGF, shown to be a key cause of the excess growth and leakiness of ocular blood vessels that result in loss of vision in these patients. Current VEGF antagonists, such as Lucentis, slow this vision loss, but require injections into the eye every four weeks, a particular issue for elderly patients who often have limited mobility. Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period for Proposed Purchase of Shares by Dr. Phillip Frost Thursday July 12, 8:00 am ET MIAMI July 12 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced that that the U.S. Department of Justice has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the potential acquisition of additional shares of Opko Health common stock by Dr. Phillip Frost, CEO and Chairman of Opko. Dr. Frost has requested clearance to purchase additional shares of Opko Health common stock, which this action by the Justice Department now makes feasible.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OPK
Current Price
Volume:
Bid Ask Day's Range
OPK News: Statement of Changes in Beneficial Ownership (4) 05/23/2017 07:05:12 AM
OPK News: MabVax Therapeutics Announces the Closing of its $4.1 Million Public Offering 05/22/2017 07:00:00 AM
OPK News: Xenetic Biosciences Receives Program Update from Partner Shire’s Phase 1/2 Study Evaluating SHP656 in Development as a Long... 05/22/2017 07:00:00 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 05/22/2017 06:49:56 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 05/19/2017 06:50:44 AM
News News Alert: Statement of Changes in Beneficial Ownership (4) 05/23/2017 07:05:12 AM
PostSubject
#5325   Those who still own Hope you put now invest 05/23/17 10:42:41 AM
#5323   I agree completely. So glad I got DegenerateGambler 05/22/17 06:58:52 PM
#5322   Glad i got out of this when i seppi08162 05/22/17 02:05:12 PM
#5321   My sentiment exactly. Picked some up at $6.58 game7alcs 05/16/17 07:55:36 PM
#5320   Me too Got some at 6.65 and 6.59 today This Juice555 05/16/17 05:42:03 PM
#5319   I couldn't resist picking up some more here game7alcs 05/16/17 04:37:25 PM
#5318   The BOD meeting is coming up.... I filled now invest 05/16/17 12:42:53 PM
#5317   I think Frost is a senile old man. Matrix999 05/16/17 08:37:01 AM
#5316   Now Invest IMO Dr. Frost will "ramp up" tredenwater2 05/15/17 03:46:06 PM
#5315   WEll... today they are presenting several items at now invest 05/15/17 10:26:23 AM
#5314   well... Frost bought over a million shares yesterday... now invest 05/11/17 09:55:28 AM
#5313   Recent launches in the renal market have typically junewong 05/11/17 01:23:29 AM
#5312   Since OPK has the $1 B from the Sky10 05/10/17 03:38:55 PM
#5310   Well... that would be interesting.... 3 now invest 05/10/17 01:58:40 PM
#5309   Selling OPK was the best thing that happened seppi08162 05/10/17 12:24:31 PM
#5308   Patience is a V I R T U E.... Frost007 05/10/17 12:10:32 PM
#5307   OPK........3 Little Birds stated, "Buy Out...Look out shorts"... Frost007 05/10/17 11:15:18 AM
#5306   Ouch stonsetr 05/10/17 10:47:03 AM
#5305   Frost should step down AS CEO.... IMO Just now invest 05/10/17 09:58:47 AM
#5304   Down 10% thanks frost Sone 05/10/17 09:26:19 AM
#5303   That call was an amateur hour production!!!! now invest 05/10/17 08:35:26 AM
#5302   From the conference call my take is another game7alcs 05/10/17 08:01:39 AM
#5301   Haha lol yea I agree with you OPKO Serving game7alcs 05/09/17 07:15:56 PM
#5300   OPKO-Bringing You Today's Technologies Tomorrow...Maybe joe_techi 05/09/17 07:12:02 PM
#5299   OPKO - working at a snails pace That should game7alcs 05/09/17 06:15:42 PM
#5298   $6 here we come..,, Sone 05/09/17 04:25:19 PM
#5297   And down we go..... Sone 05/09/17 04:23:59 PM
#5296   Nice move. I'm not doing anything right now game7alcs 05/08/17 10:33:38 PM
#5295   I bought some calls just in case we Picks77 05/08/17 06:01:09 PM
#5294   We should start getting a better indication on game7alcs 05/08/17 03:00:25 PM
#5293   I guess we see $6 tomorrow.. Sone 05/08/17 02:54:49 PM
#5292   Earnings after close tomorrow !! now invest 05/08/17 01:59:00 PM
#5290   Very good summation. I can't say I disagree game7alcs 05/01/17 02:23:41 PM
#5289   all I can say... is that while I now invest 05/01/17 11:54:37 AM
#5288   What is going on? Are we just a game7alcs 05/01/17 11:36:04 AM
#5287   See we will be getting the notices for now invest 05/01/17 11:06:16 AM
#5286   I agree with yoy game7alcs 04/27/17 12:19:34 PM
#5285   OPK did get something like $1M worth of joe_techi 04/27/17 11:16:11 AM
#5284   This is the type of thing that actually now invest 04/27/17 09:46:46 AM
#5283   The recent financing is stay alive money. More joe_techi 04/25/17 07:16:36 AM
#5282   Been eyeing them for a while Seems like good Juice555 04/25/17 12:26:57 AM
#5281   Just made an investment in Cocrystal Pharma joe_techi 04/25/17 12:01:32 AM
#5280   He should buy MannKind and monetize their Phaeton 04/24/17 11:56:45 PM
#5279   Even though I called it I missed the game7alcs 04/19/17 11:03:18 AM
#5278   Thanks Highly appreciate your input I agree with you what Juice555 04/19/17 10:11:19 AM
#5277   Sorry... but have to disagree with you... OPK now invest 04/19/17 10:08:04 AM
#5276   Yeah Very painful Let's hope Dr. Frost is eyeing another Juice555 04/18/17 06:38:36 PM
#5275   Ok I can say I would never thought game7alcs 04/18/17 05:20:47 PM
#5274   Well.... FROST JUST TAKES HIS TIME..... now invest 04/17/17 12:28:25 PM
#5273   $OPK - back in at $7.53 Atlanta1 04/13/17 02:01:56 PM
PostSubject